Genprex (DB:2DE0) - Stock Price, News & Analysis

2DE0 Stock Overview

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes.

About the company

2DE0 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Risk Analysis

Shares are highly illiquid

Does not have a meaningful market cap (€4M)

Makes less than USD$1m in revenue ($0)

Earnings are forecast to decline by an average of 8.3% per year for the next 3 years

+ 2 more risks

Genprex, Inc. Competitors

co.don

XTRA:CNW

€6.5m

bioXXmed

XTRA:T5O

€2.4m

Deutsche Biotech Innovativ

DUSE:DBI

€947.3k

2invest

XTRA:2INV

€49.4m

Price History & Performance

Summary of all time highs, changes and price drops for Genprex
Historical stock prices
Current Share Price	US$6.50
52 Week High	US$37.82
52 Week Low	US$6.50
Beta	-0.63
1 Month Change	0%
3 Month Change	-21.95%
1 Year Change	-77.49%
3 Year Change	-94.98%
5 Year Change	-89.73%
Change since IPO	-98.60%

Recent updates

Shareholder Returns

	2DE0	DE Biotechs	DE Market
7D	0%	-1.2%	1.7%
1Y	-77.5%	-23.0%	2.3%

Return vs Industry: 2DE0 underperformed the German Biotechs industry which returned -22.4% over the past year.

Return vs Market: 2DE0 underperformed the German Market which returned 2.2% over the past year.

Price Volatility

Is 2DE0's price volatile compared to industry and market?
2DE0 volatility
2DE0 Average Weekly Movement	n/a
Biotechs Industry Average Movement	5.0%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.1%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: 2DE0's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine 2DE0's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2009	26	John Varner	www.genprex.com

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) that is in Phase 1/2 and 2 clinical trials to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002 for the treatment of type 1 diabetes, and GPX-003 for the treatment of type 2 diabetes.

Genprex, Inc. Fundamentals Summary

How do Genprex's earnings and revenue compare to its market cap?
2DE0 fundamental statistics
Market cap	€4.12m
Earnings (TTM)	-€28.83m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.1x

P/E Ratio

Is 2DE0 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2DE0 income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$30.86m
Earnings	-US$30.86m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-16.15
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did 2DE0 perform over the long term?

See historical performance and comparison

2DE0 Stock Overview

Rewards

Risk Analysis

Genprex, Inc. Competitors

XTRA:CNW

€6.5m

XTRA:T5O

€2.4m

DUSE:DBI

€947.3k

XTRA:2INV

€49.4m

Price History & Performance

Recent News & Updates

Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer

Genprex, Inc. has completed a Follow-on Equity Offering.

Genprex, Inc. has filed a Follow-on Equity Offering.

Genprex, Inc. has filed a Follow-on Equity Offering.

Genprex, Inc. Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers

Genprex, Inc. Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators

Recent updates

Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer

Genprex, Inc. has completed a Follow-on Equity Offering.

Genprex, Inc. has filed a Follow-on Equity Offering.

Genprex, Inc. has filed a Follow-on Equity Offering.

Genprex, Inc. Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers

Genprex, Inc. Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators

Genprex, Inc. Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa Therapy in Combination with Tagrisso to Treat Non-Small Cell Lung Cancer

New major risk - Market cap size

No longer forecast to breakeven

Genprex, Inc. to Present Data on the Use of Reqorsa for the Treatment of Lung Cancers At 2023 Aacr-Nci-Eortc International Conference on Molecular Targets and Cancer Therapeutics

Genprex Receives Non-Compliance Notice From Nasdaq

Genprex Appoints Suzanne Thornton-Jones as Senior Vice President, Regulatory Affairs

Genprex, Inc. announced delayed 10-Q filing

Genprex, Inc. Receives Fast Track Designation from the FDA for Its Small Cell Lung Cancer Drug Candidate

Genprex, Inc. Grants Chinese Patent for REQORSA(R) Immunogene Therapy in Combination with PD-1 Antibodies to Treat Cancers

Genprex Receives U.S. FDA Fast Track Designation for REQORSA Immunogene Therapy in Combination with Tecentriq for the Treatment of Small Cell Lung Cancer

Genprex, Inc. Receives Safety Review Committee Approval to Advance to Phase 2 Expansion Portion of Acclaim-1 Clinical Trial of REQORSA(R) in Combination with Tagrisso(R) in Advanced Non-Small Cell Lung Cancer

Genprex, Inc. Publishes Positive Clinical Data from Phase 1 Portion of Acclaim-1 Clinical Trial Evaluating Reqorsa Immunogene Therapy in Non-Small Cell Lung Cancer

Genprex, Inc. announced delayed 10-Q filing

No longer forecast to breakeven

High number of new directors

High number of new and inexperienced directors

Genprex Receives Safety Review Committee Approval to Proceed to Final Cohort in Acclaim-1 Phase 1 Dose Escalation Trial of REQORSA(R) in Combination with Tagrisso(R) in Advanced Non-Small Cell Lung Cancer

High number of new and inexperienced directors

High number of new and inexperienced directors

Genprex Announces Safety Review Committee Approves Dose Escalation in Acclaim-1 Phase 1/2 Trial of REQORSA™ in Combination with Tagrisso® in Non-Small Cell Lung Cancer

High number of new and inexperienced directors

Genprex, Inc. Announces the Opening for Enrollment of its Phase 1/2 Acclaim-2 Clinical Trial of REQORSA™ Immunogene Therapy in Combination With Keytruda® to Treat Non-Small Cell Lung Cancercer

Genprex, Inc. Announces First Patient Dosed in Phase 1/2 Acclaim-1 Clinical Trial of REQORSA Immunogene Therapy in Combination with Tagrisso to Treat Non-Small Cell Lung Cancer

Genprex, Inc. Announces First Patient Dosed in Phase 1/2 Acclaim-1 Clinical Trial of REQORSA Immunogene Therapy in Combination with Tagrisso to Treat Non-Small Cell Lung Cancer

Genprex, Inc. Announces Positive Preclinical Data for Use of Genprex’s ONCOPREX® Nanoparticle Delivery System for Delivery of FAS DNA Plasmid to Treat Metastatic Colorectal Cancer

Genprex, Inc. to Accelerate Opening of Acclaim-1 Clinical Trial Sites

Genprex Expands Gene Therapy Oncology Pipeline to Include Small Cell Lung Cancer

Genprex Receives U.S. FDA Fast Track Designation for REQORSA™ Immunogene Therapy in Combination With Keytruda® for the Treatment of Non-Small Cell Lung Cancer

Genprex, Inc.(NasdaqCM:GNPX) dropped from Russell 3000E Index

Genprex Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer Following FDA Review

Forecast to breakeven in 2024

Genprex Announces Centralized Institutional Review Board Approval for Acclaim-1 Clinical Trial in Non-Small Cell Lung Cancer

Genprex Initiates Site Recruitment for Acclaim-2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer

Genprex, Inc. Announces Formation of Clinical Advisory Board

Genprex, Inc. Achieves Major Manufacturing Milestone for REQORSA™ Immunogene Therapy for Upcoming Trials to Treat Non-Small Cell Lung Cancer

Genprex, Inc. Completes Manufacturing Scale-Up for Clinical-Grade Production of REQORSA™ Immunogene Therapy for Upcoming Acclaim-1 and Acclaim-2 Clinical Trials For Lung Cancer

Genprex, Inc Completes Manufacturing Technology Transfer for Novel Gene Therapy

Genprex Initiates Site Recruitment for Acclaim-1 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer

Genprex, Inc. Appoints George K. Gittes to Its Scientific Advisory Board

Genprex, Inc. Promotes Eric Chapdelaine to Vice President of Manufacturing

Genprex, Inc. Names Thomas C. Gallagher, Esq. as Senior Vice President of Intellectual Property and Licensing

Shareholder Returns

Price Volatility

About the Company

Genprex, Inc. Fundamentals Summary

0.0x

-0.1x

Earnings & Revenue